We are a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. Our proprietary targeted protein degradation platform, which we refer to as Pegasus, allows us to discover highly selective small molecule protein degraders with potent activity against disease-causing proteins throughout the body. We believe that our small molecule protein degraders have significant advantages over existing therapies and allow us to address a large portion of the human genome that was previously intractable with traditional modalities.
To date, we have utilized our Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology.
|Industry:||BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)|
|Address||200 Arsenal Yards Blvd., Suite 230, Watertown, MA 02472, US|
|Phone Number||(857) 285-5300|
|View Prospectus:||Kymera Therapeutics|
|Revenues||$9.5 mil (last 12 months)|
|Net Income||$-56.9 mil (last 12 months)|
|Price range||$20.00 - $20.00|
|Est. $ Volume||$173.7 mil|
|Manager / Joint Managers||Morgan Stanley/ BofA Securities/ Cowen and Company/ Guggenheim Securities|
|Expected To Trade:||8/21/2020|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|